Effects of C-glycosylation on anti-diabetic, anti-Alzheimer's disease and anti-inflammatory potential of apigenin

Food and Chemical Toxicology

Volumn 64, Issue , 2014, Pages 27-33

  Choi, Jae Sue ^a   Nurul Islam, Md ^a   Yousof Ali, Md ^a   Kim, Eon Ji ^a   Kim, Young Myeong ^b   Jung, Hyun Ah ^c  

^a Pukyong National University   (South Korea)

^b Kangwon National University   (South Korea)

^c Chonbuk National University   (South Korea)

Author keywords

Alzheimer's disease; Apigenin derivative; Diabetic complication; Flavonoid; Inflammation

Indexed keywords

ACETYLCHOLINESTERASE; ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; APIGENIN; BETA SECRETASE; BETA SECRETASE 1; CHOLINESTERASE; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOVITEXIN; LIPOPOLYSACCHARIDE; NITRIC OXIDE; PROTEIN TYROSINE PHOSPHATASE 1B; VITEXIN;

ALZHEIMER DISEASE; ANIMAL TISSUE; ANTI ALZHEIMER ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LINE; CELL STRAIN RAW 264; DRUG ACTIVITY; DRUG DETERMINATION; DRUG POTENCY; ENZYME INHIBITION; GLYCOSYLATION; HUMAN; IN VITRO STUDY; NONHUMAN; RAT;

RATTUS;

2-AMINO-5,6-DIHYDRO-6-METHYL-4H-1,3-THIAZINE HYDROCHLORIDE; 3-[4,5-DIMETHYLTHIAZOL-2-YL]-2,5-DIPHENYL TETRAZOLIUM BROMIDE; 5,5′-DITHIOBIS [2-NITROBENZOIC ACID]; ACETYLCHOLINESTERASE; ACETYLTHIOCHOLINE IODIDE; ACH; ACHE; AD; ADVANCED GLYCATION ENDPRODUCTS; AGES; ALDOSE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ALZHEIMER'S DISEASE; AMT; AMYLOID-Β PEPTIDES; APIGENIN DERIVATIVE; APP; AR; ARI; AΒ; BACE1; BCH; BCHE; BUTYRYLCHOLINESTERASE; BUTYRYLTHIOCHOLINE CHLORIDE; CHAT; CHOLINE ACETYLTRANSFERASE; COX-2; CYCLOOXYGENASE-2; DIABETIC COMPLICATION; DMEM; DTNB; DULBECCO'S MODIFIED EAGLE'S MEDIUM; EDTA; ETHYLENEDIAMINETETRAACETIC ACID; FBS; FETAL BOVINE SERUM; FLAVONOID; HORSERADISH PEROXIDASE; HRAR; HRP; HUMAN RECOMBINANT ALDOSE REDUCTASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMATION; INOS; LIPOPOLYSACCHARIDE; LPS; MTT; NADPH; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NO; NOS; P-NITROPHENYL PHOSPHATE; PNPP; POLYVINYLIDENE FLUORIDE; PROTEIN TYROSINE PHOSPHATASE 1B; PTP1B; PVDF; RAT LENS ALDOSE REDUCTASE; REACTIVE OXYGEN SPECIES; RLAR; ROS; Β-NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; Β-SITE AMYLOID PRECURSOR; Β-SITE AMYLOID PRECURSOR CLEAVING ENZYME 1;

ALZHEIMER DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; APIGENIN; CELL LINE; GLYCOSYLATION; HYPOGLYCEMIC AGENTS; MICE;

EID: 84890034659     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.11.020     Document Type: Article

References (41)

1. Adamo M., Raizada M.K., LeRoith D. Insulin and insulin-like growth factor receptors in the nervous system. Mol. Neurobiol. 1989, 3:71-100.
2. Agnese A.M., Pierez C., Cabrera J.L. Adesmia aegiceras: antimicrobial activity and chemical study. Phytomedicine 2001, 8:389-394.
3. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 2005, 67:3-21.
4. Asante A.E., Kennedy B.P. Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am. J. Physiol.: Endocrinol. Metab. 2003, 284:663-670.
5. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann. Rev. Med. 1995, 46:223-234.
6. Butterfield D.A., Reed T., Newman S.F., Sultana R. Roles of amyloid β-peptideassociated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 2007, 43:658-677.
7. Chi Y.S., Cheon B.S., Kim H.P. Effect of wogonin, a plant flavone from Scutellaria radix, on the suppression of cyclooxygenase and the induction of inducible nitric oxide synthase in lipolpolysaccharide-treated RAW 264.7 cells. Biochem. Pharmacol. 2001, 61:1195-1203.
8. Choo C.Y., Sulong N.Y., Man F., Wong T.W. Vitexin and isovitexin from the leaves of Ficus deltoidea with in-vivo α-glucosidase inhibition. J. Ethnopharmacol. 2012, 142:776-781.
9. Cui L., Na M., Oh H., Bae E.Y., Jeong D.G., Ryu S.E., Kim S., Kim B.Y., Oh W.K., Ahn J.S. Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg. Med. Chem. Lett. 2006, 16:1426-1429.
10. 13C NMR chemical shifts of flavonoids. Magn. Reson. Chem. 2007, 45:835-845.
11. de la Monte S.M. Insulin resistance and Alzheimer's disease. BMB Rep. 2009, 42:475-481.
12. Ellman G.L., Courtney K.D., Andres V.J., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
13. Esmail A., Marjan N., Mahsa S., Mehdi S. Neuroprotective effects of vitexin, a flavonoid, on pentylenetetrazole-induced seizure in rats. Chem. Biol. Drug Des. 2012, 80:274-278.
14. Evin G., Lessene G., Wilkins S. BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity. Recent Pat. CNS Drug Disc. 2011, 6:91-106.
15. Feldman E.L., Stevens M.J., Greene D.A. Pathogenesis of diabetic neuropathy. Clin. Neurosci. 1997, 4:365-370.
16. Fu Y., Zu Y., Liu W., Lin Zhang L., Tong.M., Efferth T., Kong Y., Hou C., Chen L. Determination of vitexin and isovitexin in pigeonpea using ultrasonic extraction followed by LC-MS. J. Sep. Sci. 2008, 31:268-275.
17. Giacobini E. The cholinergic system in Alzheimer disease. Prog. Brain Res. 1990, 84:321-332.
18. Havsteen B.H. The biochemistry and medicinal significance of the flavonoids. Pharmacol. Ther. 2002, 96:67-202.
19. Hayman S., Kinoshita J.H. Isolation and properties of lens aldose reductase. J. Biol. Chem. 1965, 240:877-882.
20. Johnson T.O., Ermolieff J., Jirousek M.R. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat. Rev. Drug Discov. 2002, 1:696-709.
21. Kawanishi K., Ueda H., Moriyasu M. Aldose reductase inhibitors from the nature. Curr. Med. Chem. 2003, 10:1353-1374.
22. Kim B.J., Kim J.H., Heo M.Y., Kim H.P. Antioxidant and anti-inflammatory activities of the Mung Bean. Cosmet. Toiletries 1998, 113:71-74.
23. Kune S., Takeya M., Mori T., Araki N., Susuki H., Horiuchi S., Kodama T. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 1978, 86:271-278.
24. Kwon S.H., Lee H.K., Kim J.A., Hong S.I., Kim H.C., Jo T.H., Park Y.I., Lee C.K., Kim Y.B., Lee S.Y., Jang C.G. Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice. Eur. J. Pharamacol. 2010, 649:210-217.
25. Lau F.C., Shukitt H.B., Joseph J.A. Nutritional intervention in brain aging: reducing the effects of inflammation and oxidative stress. Subcell. Biochem. 2007, 42:299-318.
26. Lin J.Y., Tang C.Y. Strawberry, loquat, mulberry, and bitter melon juices exhibit prophylactic effects on LPS-induced inflammation using murine peritoneal macrophages. Food Chem. 2008, 107:1587-1596.
27. Lin C.M., Huang S.T., Liang Y.C., Lin M.S., Shih C.M., Chang Y.C., Chen T.Y., Chen C.T. Isovitexin suppresses lipopolysaccharide-mediated inducible nitric oxide synthase through inhibition of NF-kappa B in mouse macrophages. Planta Med. 2005, 71:748-753.
28. Mari H., Riina N., Pia V., Marina H., Eeva M. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit stat-1 and NF-κB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-κB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediat. Inflamm. 2007, 2007:1-10.
29. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991, 43:109-142.
30. Neumann K.F., Rojo L., Navarrete L.P., Farias G., Reyes P., Maccioni R.B. Insulin resistance and Alzheimer's disease: molecular links and clinical implications. Curr. Alzheimer Res. 2008, 5:438-447.
31. Nishimura C., Yamaoka T., Mizutani M., Yamashita K., Akera T., Tanimoto T. Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system. Biochim. Biophys. Acta 1991, 1078:171-178.
32. Rijke E.D., Out P., Niessen W.M.A., Ariese F., Goojer C., Brinkman U.A.T. Analytical separation and detection methods for flavonoids. J. Chromatogr. 2006, 1112:31-63.
33. Santiago J.V. Lessons from the diabetes control and complications trial. Diabetes 1993, 42:1549-1554.
34. Sima A.A. Encephalopathies: the emerging diabetic complications. Acta Diabetol. 2010, 47:279-293.
35. Tiraboschi P., Hansen L.A., Alford M., Merdes A., Mashah E., Thal L.J., Corey B.J. Early and widespread cholinergic losses differentiate Dementia with Lewi Bodies from Alzheimer's disease. Arch. Gen. Psychiatr. 2002, 59:946-951.
36. Torreilles F., Salman-Tabcheh S., Guérin M., Torreilles J. Neurodegenerative disorders: the role of peroxynitrite. Brain Res. Rev. 1999, 30:153-163.
37. Vinson J.A., Howard III T.B. Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J. Nutr. Biochem. 1996, 7:659-663.
38. Vitek M.P., Bhattacharya K., Glendening J.M., Stopa E., Vlassara H., Bucala R., Manogue K. Advanced glycation end-products contribute to amyloidosis in Alzheimer's disease. Proc. Natl. Acad. Sci. 1994, 91:4766-4770.
39. Yegang D., Hung C., Ivan K.C., Clive L. CYP93G2 Is a flavanone 2-hydroxylase required for C-glycosylflavone biosynthesis in rice. Plant Physiol. 2010, 154:324-333.
40. Zhang Y., Bao B., Lu B., Ren Y., Tie X., Zhang Y. Determination of flavone C-glucosides in antioxidant of bamboo leaves (AOB) fortified foods by reversed-phase high-performance liquid chromatography with ultraviolet diode array detection. J. Chromatogr. A 2005, 1065:177-185.
41. Zheng Q.S., Sun X.L., Xubo Li G., Song M., Wang C.H. Protective effects of luteolin-7-glucoside against liver injury caused by carbon tetrachloride in rats. Pharmazie 2004, 59:286-289.